AstraZeneca PLC:s resultatrapport för de första nio månaderna och tredje kvartalet 2016
Resultatet för tredje kvartalet är i linje med våra förväntningar
Ämnen: Farmaci
-
-
Lynparza Phase III SOLO-2 trial shows significant progression-free survival benefit
Trial studied Lynparza as maintenance treatment for women with BRCA-mutated metastatic ovarian cancer Initial findings show safety profile with Lynparza tablets was consistent with previous studies
-
FDA accepts for review New Drug Application for sodium zirconium cyclosilicate (ZS-9) for the treatment of hyperkalaemia
AstraZeneca today announced that the US Food and Drug Administration (FDA) has accepted a complete re-submission of a New Drug Application (NDA) for sodium zirconium cyclosilicate (ZS-9), a potential new medicine for the treatment of hyperkalaemia (high potassium level in the blood serum) by ZS Pharma, a wholly-owned subsidiary of AstraZeneca. The FDA has indicated that this is a complete class 2
-
AstraZeneca enters agreement with Cilag GmbH International to divest rights to Rhinocort Aqua outside the US
AstraZeneca today announced that it has entered into an agreement with Cilag GmbH International, an affiliate of Johnson & Johnson, for the divestment of the rights to Rhinocort Aqua outside the US.
-
AstraZeneca enters agreement with Aralez for beta-blocker medicine Toprol-XL in the US
AstraZeneca today announced that it has entered into an agreement with Aralez Pharmaceuticals Trading DAC, a subsidiary of Aralez Pharmaceuticals Inc., for the rights to branded and authorised generic Toprol-XL (metoprolol succinate) in the US
-
AstraZeneca reports top-line results from the Brilinta EUCLID trial in patients with peripheral artery disease
Brilinta did not demonstrate a benefit over clopidogrel in a symptomatic peripheral artery disease patient population
-
MedImmune out-licenses potential medicine for inflammatory diseases to Allergan
AstraZeneca today announced that MedImmune, its global biologics research and development arm, has entered into a licensing agreement with Allergan plc for the global rights to MEDI2070.
-
AstraZeneca presents new data on Faslodex in breast cancer and provides immuno-oncology update at ESMO 2016 congress
Phase III FALCON trial demonstrates superiority of Faslodex over Arimidex in the 1st-line treatment of hormone-receptor positive (HR+) advanced breast cancer Immuno-Oncology data reinforce commitment to lung and head and neck cancers
-
AstraZeneca provides update on cediranib EU marketing authorisation application
AstraZeneca today announced its decision to withdraw the Marketing Authorisation Application (MAA) submitted to the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) in June 2015 for cediranib in combination with platinum-based chemotherapy
-
Phase III combination trial of Bydureon and Forxiga shows significant benefits in patients with type-2 diabetes
DURATION-8 trial met primary and secondary endpoints, significantly reducing blood sugar (HbA1c), weight and systolic blood pressure versus either medicine alone The first trial to assess GLP-1RA/SGLT-2i combination therapy
-
Stora skillnader i vården av typ-2 diabetes i Danmark, Norge och Sverige enligt ny studie som presenteras på EASD
Kontrollen av blodsocker och kolesterol hos patienter med typ 2-diabetes är bättre i Danmark jämfört med i Norge och i Sverige enligt resultat från studien Nordic DISCOVER. Studien är den första nordiska jämförande långsiktiga studien av primärvårdens omhändertagande av patienter med typ 2-diabetes. Resultat presenteras för första gången på den europeiska diabeteskonferensen EASD, 14 september.
-
Fördubblade sjukdomskostnader i Sverige för typ 2-diabetes under åren 2006 – 2014. Följdsjukdomar som stroke och hjärtinfarkt kostar allt mer
Sjukdomskostnaderna för behandling av patienter med typ 2-diabetes fördubblades i Sverige mellan åren 2006 och 2014 samtidigt som kostnaderna för diabetesläkemedel genomgående under perioden endast representerar fyra procent. Det visar resultat från den svenska studien DAISY som presenteras på den europeiska diabeteskonferensen EASD, den 13 september.
-
AstraZeneca announces two new phase IIIb trials for Forxiga in chronic kidney disease and chronic heart failure
First programme to assess potential cardiovascular and renal benefit of an SGLT-2i beyond diabetes
-
Benralizumab Phase III trials show positive results in severe asthma
AstraZeneca’s first biologic respiratory medicine met primary and key secondary endpoints in pivotal trials for severe asthma
-
AstraZeneca to present new data highlighting its growing respiratory portfolio and pipeline at European Respiratory Society 2016
New evidence to be presented includes pivotal Phase III data on benralizumab
-
AstraZeneca to sell small molecule antibiotics business to Pfizer
Value-creating divestment supports AstraZeneca’s focus on three main therapy areas Pfizer’s dedicated focus on infectious diseases will extend the reach of the antibiotics to more patients globally and maximise the potential of the late-stage, small molecule antibiotics business
-
AstraZeneca and Lilly receive FDA Fast Track designation for AZD3293, an investigational treatment for early Alzheimer’s disease
Administration (FDA) Fast Track designation for the development programme in Alzheimer’s disease for AZD3293, an oral beta secretase cleaving enzyme (BACE) inhibitor currently in Phase III clinical trial. The FDA’s Fast Track programme is designed to expedite the development and review of new therapies to treat serious conditions and tackle key unmet medical needs.
-
AstraZeneca announces investment in Moderna
AstraZeneca today announced that it has increased its equity interest in Moderna Therapeutics (Moderna) with a $140 million investment as part of Moderna’s preferred-stock financing.
-
AstraZeneca provides update on phase III trial of selumetinib in non-small cell lung cancer
Selumetinib did not meet trial endpoint of progression-free survival in KRASm NSCLC patients.
-
AstraZeneca PLC:s resultatrapport för första halvåret och andra kvartalet 2016
De totala intäkterna minskade som förväntat med 3%, vilket återspeglar en minskning i produktförsäljning med 2% och är drivet av patentutgångar, i synnerhet Crestor i USA. Merparten av intäkterna från externa samarbeten förväntas ligga under andra halvåret.
Visa mer
Loading...